Valneva SE, a prominent player in the biotechnology sector, has been making significant strides in the health care industry with its focus on developing and commercializing vaccines for infectious diseases. Based in Nantes, France, Valneva SE operates on a global scale, leveraging its expertise to address some of the most pressing health challenges of our time.
As of June 18, 2026, Valneva SE’s stock closed at 2.305 EUR, reflecting a market capitalization of 437.14 million EUR. Despite a challenging year, with the stock reaching a 52-week low of 2.135 EUR on May 3, 2026, the company has shown resilience and potential for growth. The 52-week high of 5.415 EUR, recorded on August 17, 2025, underscores the volatility and opportunities within the biotech sector.
Valneva SE’s product portfolio includes IXIARO/JESPECT, a vaccine indicated for the prevention of Japanese encephalitis, and Dukoral, which is used to prevent cholera and diarrhea caused by enterotoxigenic Escherichia coli, particularly for travelers. These products highlight the company’s commitment to addressing global health needs and its ability to bring innovative solutions to market.
Beyond its existing products, Valneva SE is actively developing vaccines for a range of infectious diseases, including Clostridium difficile, Lyme disease, chikungunya, and Zika. These efforts are part of the company’s broader strategy to expand its impact on public health and to meet the growing demand for vaccines in an increasingly interconnected world.
A key component of Valneva SE’s success is its proprietary EB66 vaccine production cell line and IC31 adjuvant. These technologies form the backbone of the company’s vaccine development efforts, enabling it to produce effective and safe vaccines. Through strategic collaborations, service agreements, and licensing deals with biopharmaceutical and pharmaceutical companies, as well as academic institutions, Valneva SE continues to enhance its technological capabilities and expand its reach.
Since its initial public offering on June 29, 2007, Valneva SE has established itself as a leader in the biotech industry. Listed on the NYSE Euronext Paris, the company remains committed to its mission of developing vaccines that address unmet medical needs and improve global health outcomes.
As Valneva SE navigates the complexities of the biotech landscape, its focus on innovation, collaboration, and strategic growth positions it well to overcome challenges and capitalize on opportunities. With a strong foundation and a clear vision for the future, Valneva SE is poised to continue making significant contributions to the field of infectious disease prevention and treatment. For more information, interested parties can visit the company’s website at www.valneva.com .
